CN100342888C - Chinese medicine preparation for treating prostatic hyperplasia - Google Patents
Chinese medicine preparation for treating prostatic hyperplasia Download PDFInfo
- Publication number
- CN100342888C CN100342888C CNB2005100539198A CN200510053919A CN100342888C CN 100342888 C CN100342888 C CN 100342888C CN B2005100539198 A CNB2005100539198 A CN B2005100539198A CN 200510053919 A CN200510053919 A CN 200510053919A CN 100342888 C CN100342888 C CN 100342888C
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- preparation
- medicine preparation
- powder
- semen vaccariae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a traditional Chinese medicine preparation for treating prostatic hyperplasia. The traditional Chinese medicine preparation is prepared from astragalus root, sargentgloryvine stem, cowherb seed, cattail pollen, notoginseng, leech, etc.
Description
Technical field:
The present invention relates to a kind of Chinese medicine preparation for the treatment of prostatic hyperplasia, the particularly Chinese medicine preparation made from Chinese medicines such as the Radix Astragali, Caulis Sargentodoxae, Semen Vaccariae, Pollen Typhae, Typhonium flagelliforme (Lodd.) Blume, Hirudos.
Background technology:
Hyperplasia of prostate is equivalent to the traditional Chinese medical science " smart infirmity ", " old man's pouring ", is a kind of benign proliferative diseases of prostata tissue.Be one of common male's senile disease.Male more than 50 years old all has prostatic hyperplasia in various degree.Domestic data report, sickness rate accounts for more than 55% more than 60 years old, and with age increase, the also corresponding increase of its sickness rate.Traditional Chinese medical science ancient books claims that primary disease is " difficulty in urination ", and " smart infirmity " is doctor family name in modern age." difficulty in urination " head sees " interior warp ", as " Ling Shu Miraculous Pivot or Divine Axis. this is defeated " piece of writing says: " three warmers ... the difficulty in urination actually, void is incontinence of urine then." " element is asked ": " dysfunction of the urinary bladder is infirmity, is not about incontinence of urine." " Compendium of medicine ": " difficulty in urination one of closes name of disease also.Branch, have sudden and violent of a specified duration very, lid the person of closing close cruelly, closes for drowning, and drop does not go out, and popular name urinary obstruction is also.Infirmity person's prolonged illness is difficult unination symptom-complex, dripping drop and going out, tens of times or hundred times on the one." primary disease is with frequent micturition, dysuria, the sound of rain pattering not to the utmost, even urine retention is a Clinical symptoms.After its morbidity was more common in 50 years old, symptom appearred seldom before this.Each is cured all consistent BPH of thinking of family and belongs to the traditional Chinese medical science " difficulty in urination ", " stranguria " category, but its pathogeny is then respectively had argumentation.Wang Xingzhu, Hu are attained, the medium BPH of thinking of Fan Xue is the card that deficiency in origin and excess in superficiality, apoplexy due to deficiency are held reality under the arm, it is empty that void is that internal organs such as lung spleen kidney lose, actually be QI and blood phlegm-turbidity and blood stasis knot, water channel is obstructed, and (Wang Xingzhu dredges spring soup and treats old hyperplasia of prostate 72 examples [J] the Shaanxi traditional Chinese medical science, 2002, recklessly attain yang invigorating collateral dredging soup treatment hyperplasia of prostate 20 examples [J] Chinese Chinese medicine information magazine, 2002,9 (9): 53) at 23 (4): 315.Fan Xuezhong think stagnation of QI due to depression of the liver also can cause functioning of bladder unfavorable and fall ill (the new traditional Chinese medical science of hyperplasia of prostate 217 examples [J] is treated in hard masses softening and resolving blood stasis dispelling the turbid descending clearing away heat-damp and promoting diuresis ruling by law among the Fan Xue, 1999,31 (12): 26); What He Hongbing, the refined equality of Wei then proposed the diseases caused by exogenous pathogenic factor damp-heat flowing down to the urinary bladder says that (He Hongbing treats aged hyperplasia of prostate 72 examples [J] Anhui tcm clinical practice magazine from stasis of blood differentiation of symptoms and signs for classification of syndrome, 2001,13 (3): 181 Weis are refined flat, bring up the logical infirmity side's treatment of auspicious ancestor's kidney tonifying prostatic hyperplasia 50 examples [J]. the Shaanxi traditional Chinese medical science, 2002,23 (4): 317).In addition, think that primary disease is that Liver and kidney is deficient blue lifetime, due to eight extra-channel is got involved (lead to blue lifetime and mend eight extra-channel side's treatment benign prostate hyperplasia 32 examples [J]. Jilin Chinese medicine, 2002,22 (3) 19).Jiao Anqin is according to the pathogenic characteristic of deficiency in origin and excess in superficiality, with holding up first tonify deficiency, and with logical legislation with Zhi Qiben, logical stagnation resolvation disease control its mark (Jiao Anqin hyperplasia of prostate pathogenic characteristic and treatment thinking [J]. Guiyang College of Traditional Chinese Medicine's journal, 1996,18 (4): 3).Zhang Yada etc. think deficiency of kidney-QI weak for the BPH morbidity, blood stasis is the mark of primary disease, so controlling and answering the kidney invigorating is to want, do not forget blood circulation promoting and blood stasis dispelling, hard masses softening and resolving (Zhang Yada, Lu Zijie, Zhang Ping, yellow tree guiding principle kidney tonifying removing blood stasis soup treatment hyperplasia of prostate 30 examples are observed [J]. Nanjing University of Traditional Chinese Medicine's journal (natural science edition), 2001,17 (4): 216).He Hongbing, Zhang Guanrong distinguish from the stasis of blood and control, think " desire to take off spring, focus on blood stasis dispelling " (Zhang Guanrong. distinguish from the stasis of blood and to control hyperplasia of prostate 52 examples [J]. the Sichuan traditional Chinese medical science, 1998,16 (3): 24), hold concurrently, stress with having to observe and judge all cards.In addition, attain yang invigorating diuretic method recklessly, also respectively have argumentation (traditional Chinese medical science research 2003 year June 16th volume 3rd phase) to mending the eight extra-channel method blue lifetime.We think that the basic pathogenesis of hyperplasia of prostate is a blood stasis due to qi deficiency, answer benefiting QI for activating blood circulation so control, hard masses softening and resolving,
The traditional Chinese medical herbal treatment prostatic hyperplasia mainly is determination of treatment based on pathogenesis obtained through differentiation of symptoms and signs prescription and special side's proved recipe at present, and how red soldier divides the treatment of three types.The yang deficiency blood stasis blocking type is controlled with warming kidney and promoting blood circulation, the capable water of blood stasis dispelling, and the BUYANG HUANWU TANG plus-minus closes with JISHENG SHENQI WAN in the side; Qi deficiency blood stasis type is controlled with ascending the clear and descending the turbid, the capable water of blood stasis dispelling, and the BUYANG HUANWU TANG plus-minus closes with BUZHONG YIQI TANG in the side; Damp and hot folder stasis of blood type is controlled with heat clearing and blood stasis dispersing, the capable water of dampness removing, and the decoction for removing blood stasis plus-minus closes with BAZHENG SAN in the side.Total effective rate be 944% (He Hongbing treats aged hyperplasia of prostate 72 examples [J] from stasis of blood differentiation of symptoms and signs for classification of syndrome. Anhui tcm clinical practice magazine, 2001,13 (3): 181).Jiang Ji cloud five equilibrium four type opinions are controlled.The kidney qi deficiency is first with the kidney tonifying training, the ascending the clear and descending the turbid method, and the master fries in shallow oil plus-minus with big complement; Type of hyperactivity of fire caused by deficiency of YIN is controlled with nourishing YIN to lower pathogenic fire, treating stranguria sharp key, changes sanction with dabuyin pill (soup); Lower warmer wetness-heat type is controlled with clearing away heat-damp and promoting diuresis, and medicinal yun adds flavor; The turbid aperture-blocking type of the stasis of blood when pay attention to blood stasis dispelling, change turbid, regulate the flow of vital energy, sensible, a side ancestor magical effect succinum loose (Jiang Jiyun, Sun Tao, the cognition [J] that the old prostate hyperplasia typing opinion of Qian Daoqian is controlled. ShanXi Chinese Medicine Academy journal, 1998,21 (1): 21).Branch deficiency of both QI and YIN such as Zhang Yada, kidney yang deficiency, the long-pending heat of bladder, the turbid stasis of blood block four type opinions and control, and Jiao Anqin divide seven kinds of pattern of syndrome opinion to control all to obtain better curative effect [Jiao Anqin hyperplasia of prostate pathogenic characteristic and treatment thinking [J]. Guiyang College of Traditional Chinese Medicine's journal, 1996,18 (4): 3 Asias are big, Lu Zijie, Zhang Ping, yellow tree guiding principle kidney tonifying removing blood stasis soup treatment hyperplasia of prostate 30 examples are observed [J]. Nanjing University of Traditional Chinese Medicine's journal (natural science edition), 2001,17 (4): 216].The special side's proved recipe of human is also arranged, use as Wang Xingzhu and dredge spring soup, medicinal Radix Astragali Preparata, each 15g of Squama Manis (processed) (being decocted first), Cortex Cinnamomi 3g (back is down), Herba Lycopi 10g, Rhizoma Chuanxiong 6g, Concha Arcae (calcined) 30g (being decocted first), Rhizoma Alismatis 12g adds and subtracts total effective rate 929% with card.Hu Zhen [3] yang invigorating collateral dredging soup, medicinal Rhizoma Et Radix Notopterygii, Radix Puerariae, Radix Angelicae Pubescentis, Radix Angelicae Sinensis, the Rhizoma Atractylodis Macrocephalae, Rhizoma Smilacis Glabrae, Polyporus, Rhizoma Alismatis, Radix Salviae Miltiorrhizae, Squama Manis, each 10g of Bombyx Batryticatus, Hirudo 3～5g, Radix Astragali 30g, Radix Glycyrrhizae 5g is with the card plus-minus.Wei Shuping [6] intends the logical infirmity side of kidney tonifying certainly, and is medicinal: Fructus Alpiniae Oxyphyllae 30g, and Herba Ecliptae 20g, Fructus Corni, each 15g of Fructus Psoraleae, Herba Epimedii, Rhizoma Alismatis, Semen Plantaginis (decocting a drug wrapped), Herba Dianthi, Caulis Akebiae, each 10g of Rhizoma Polygoni Cuspidati, Radix Glycyrrhizae 6g, every day, 1 dose of decocting divided 2 decoction being taken warmly sooner or later.(Wang Xingzhu dredges spring soup and treats old hyperplasia of prostate 72 examples [J] the Shaanxi traditional Chinese medical science, 2002,23 (4): 315) total effective rate 88%.Mend eight extra-channel side (Semen Cuscutae 15g, Rhizoma Curculiginis 10g, Semen sojae atricolor 30g, Fructus Psoraleae 15～30g with leading to blue lifetime, Concha Ostreae 30g, Herba Lycopi 15g, Semen Vaccariae 30g, Sargassum 15g, Rhizoma Polygoni Cuspidati 15～30g, Squama Manis (processed) sheet 5g) plus-minus, total effective rate 906% (traditional Chinese medical science research the 16th the 3rd phase of volume of June in 2003).
The Chinese patent medicine of existing market treatment hyperplasia of prostate, common has:
Longbishu Jiaonang.: Fructus Psoraleae, Herba Leonuri, Herba Lysimachiae, Spora Lygodii, succinum, Pseudobulbus Cremastrae Seu Pleiones.The kidney warming activating QI, clearing heat and freeing strangury, blood circulation promoting and blood stasis dispelling, removing obstruction for relieving pain.Be used for prostatic hyperplasia.
Capsule for treating urination difficulty: Squama Manis, Cortex Cinnamomi.Movable blood soft hard, warming YANG to promote diuresis.Be used for blood stasis cohesion, functioning of bladder unfavorable due to the difficulty in urination.Or be used for early stage benign prostate hyperplasia.
Prostate disease granule: Herba Plantaginis, Radix Cyathulae, the Radix Astragali, Pollen Typhae, Herba Epimedii.Tonify Qi of the kidney, blood stasis dispelling is treating stranguria.Be used for kidney spleen deficiency, qi depression to blood stasis, prostatic hyperplasia, chronic prostatitis; The complexion rolling is white, spiritlessness and weakness, and the waist knee joint is soft unable, sagging distention in the smaller abdomen, it is not well to urinate, and drop does not go out, or frequent micturition, urgent micturition, Urethra astringent pain.
Ball relaxes in the prostatitis: Radix Rehmanniae Preparata, Semen Coicis, Semen Benincasae, Fructus Corni, Rhizoma Dioscoreae, Cortex Moutan, Rhizoma Atractylodis, Semen Persicae, Rhizoma Alismatis, Poria, Ramulus Cinnamomi, Radix Aconiti Lateralis Preparata, Semen Allii Tuberosi, Herba Epimedii, Radix Glycyrrhizae.Strengthening the body resistance, nourishing YIN for benefiting the kidney, diuresis.Be used for chronic prostatitis, prostatic hyperplasia, disease is seen frequent micturition, urgent micturition, dribbling, hematuria etc.
QIANLIETONG JIAONANG: Semen Persicae, Myrrha, Radix Salviae Miltiorrhizae, Radix Paeoniae Rubra, Flos Carthami, Herba Lycopi, Semen Vaccariae, Spina Gleditsiae, Herba Patriniae, Herba Taraxaci, Fructus Toosendan, the Radix Angelicae Dahuricae, Folium Pyrrosiae, Fructus Lycii.Blood circulation promoting and blood stasis dispelling, clearing away heat-damp and promoting diuresis.Be used for the blood stasis cohesion, the chronic prostatitis of damp invasion of lower energizer and prostatic hyperplasia.
In sum, the traditional Chinese medical herbal treatment prostatic hyperplasia has accumulated rich experience, but from bibliographical information, mainly is the determination of treatment based on pathogenesis obtained through differentiation of symptoms and signs prescription, and the Chinese patent medicine of treatment prostatic hyperplasia is few on the Chinese medicine market at present.Existing medicine belongs to a bit cures the symptoms, not the disease, and some uses expensive composition, and some is cut and interrupt using owing to uncertain therapeutic efficacy in application process.
The invention provides a kind of determined curative effect, safe ready, little, the cheap pure traditional Chinese compound medicine of side effect.
Summary of the invention:
Chinese medicine preparation of the present invention is made by Chinese medicines such as the Radix Astragali, Caulis Sargentodoxae, Semen Vaccariae, Pollen Typhae, Typhonium flagelliforme (Lodd.) Blume, Hirudos, is monarch with the Radix Astragali in its prescription, and Caulis Sargentodoxae, Semen Vaccariae are minister, and Pollen Typhae, Typhonium flagelliforme (Lodd.) Blume, Hirudo are assistant.Has benefiting QI for activating blood circulation, the effect of hard masses softening and resolving.Cure mainly the prostatic hyperplasia of blood stasis due to qi deficiency.
Radix Astragali sweet in the mouth in the dissipating blood stasis granule of prostatitis, warm in nature.Return lung, spleen channel.Benefiting qi and raising yang, inducing diuresis to remove edema, promoting pus discharge and tissue regeneration strengthening.Be " invigorating middle warmer, beneficial vigour, warm three warmers, strong taste, hemopoietic, granulation promoting, evacuation of pus expelling the toxic substance from the body with tonic, carbuncle sore panacea " (essentials of Matea Medica), so monarch drug in the side of being.The Caulis Sargentodoxae bitter in the mouth, property is flat.Return large intestine, Liver Channel, the special removing toxicity for eliminating carbuncles of merit. promoting blood circulation and stopping pain, the dehumidifying of method wind; The Semen Vaccariae bitter in the mouth, property is flat.Go into liver, stomach warp, the eliminating carbuncle of invigorating blood circulation both " was controlled pathogenic wind toxic, promoting blood circulation " (" property of medicine opinion "), again " sharp skin infection " (" pearl sac ").More than the auxilliary monarch drug benefiting QI for activating blood circulation of two flavors, poison holding doctor skin ulcer is ministerial drug in the side altogether.Pollen Typhae is sweet, and is flat, returns liver, pericardium channel, hemostasis with astringents, promoting the circulation of blood blood stasis dispelling." book on Chinese herbal medicine justice " calls its " specially go into blood system, with the gas of delicate fragrance, the circulation of qi promoting branch of holding concurrently is controlled pain of coagulation of QI-blood so can lead stasis of blood knot "; Typhonium flagelliforme (Lodd.) Blume sweet in the mouth, little hardship, warm in nature, return liver, stomach, the heart, lung, large intestine channel, hemostasis dissipating blood stasis, eliminating carbuncle eliminating stagnation; Hirudo is salty, bitter, and is flat, returns Liver Channel, kind hard masses softening and resolving, removing blood stasis.More than three flavors be altogether adjuvant drug in the side.The complete square pathogenesis that links closely is played benefiting QI for activating blood circulation, the effect of hard masses softening and resolving altogether.
Chinese medicine preparation of the present invention, its prescription is composed as follows:
Radix Astragali 1000-4000 part Caulis Sargentodoxae 500-2000 part Semen Vaccariae 333-1332 part
Pollen Typhae 266-1066 part Radix Notoginseng 100-400 part Hirudo 100-400 part
Preferred prescription is composed as follows:
Radix Astragali 1500-2666 part Caulis Sargentodoxae 750-1333 part Semen Vaccariae 499-888 part
Pollen Typhae 399-710 part Radix Notoginseng 150-266 part Hirudo 150-266 part
Most preferred prescription is composed as follows:
666.6 parts of 1000.0 parts of Semen Vaccariae of 2000.0 portions of Caulis Sargentodoxae of the Radix Astragali
200.0 parts of 200.0 portions of Hirudos of 533.4 portions of Radix Notoginseng of Pollen Typhae
In more than forming, part is a weight portion, weight is calculated with crude drug, and every part if be unit with the gram, more than forms to can be made into 1000 doses of pharmaceutical preparatioies, described 1000 doses of fingers, the final drug preparation of making, as make 1000 of capsule preparations, 1000 in tablet, granule 1000 grams, oral liquid 1000ml etc.
Can make different Packing Units as granule, as 0.5 gram-5 gram/bags.
More than form, as if being unit with the gram, can be made into the preparation of 50-1000 taking dose, as tablet, make 1000, each taking dose can be the 1-20 sheet, can take 50-1000 time altogether.As granule, make 125 bags, take the 1-2 bag at every turn, can take 62.5-125 time altogether.
More than form to be by weight as proportioning, when producing, can increase or reduce according to corresponding proportion, as large-scale production can be unit with the kilogram, or be unit with the ton, small-scale production can be unit with the milligram also, weight can increase or reduce, but the constant rate of the raw medicinal herbs weight proportion between each composition.
The ratio of above weight proportion obtains through science screening, for especial patient, and as serious symptom or light disease, fat or modest patient, the proportioning of the amount of can corresponding adjustment forming increases or reduces being no more than 100%, and drug effect is constant.
Single medicinal material, especially ministerial drug and adjuvant drug in more than forming also can be replaced by the suitable Chinese medicine with identical property of medicine, and its drug effect of the Chinese medicine preparation after the replacement is constant.
Chinese medicine preparation of the present invention is to process through extraction or other modes by the raw material of Chinese medicine that above-mentioned prescription is formed, and makes pharmaceutically active substance, subsequently, with this material is raw material, adds the medicine acceptable carrier when needing, and makes according to the routine techniques of galenic pharmacy.Described active substance can obtain by extracting raw material of Chinese medicine respectively, also can obtain by the co-extracted raw material of Chinese medicine, also can obtain by other modes, as: by pulverize, squeeze, calcine, grind, sieve, percolation, extraction, water are carried, alcohol extraction, ester are carried, methods such as ketone is carried, chromatography obtain, these active substances can be the material of extractum form, can be that dry extract also can be a fluid extract, make different concentration according to the different needs decision of preparation.
Pharmaceutically active substance in the pharmaceutical preparation of the present invention, its shared percentage by weight in preparation can be 0.1-99.9%, all the other are the medicine acceptable carrier.Pharmaceutical preparation of the present invention exists with unit dosage form, and described unit dosage form is meant the unit of preparation, as every of tablet, and capsular every capsules, every bottle of oral liquid, every bag of granule etc.
Chinese medicine preparation of the present invention can be any pharmaceutically useful dosage form, and these dosage forms comprise: tablet, sugar coated tablet, film coated tablet, enteric coated tablet, capsule, hard capsule, soft capsule, oral liquid, suck agent, granule, electuary, pill, powder, unguentum, sublimed preparation, suspensoid, powder, solution, injection, suppository, ointment, plaster, cream, spray, drop, patch.Preparation of the present invention, peroral dosage form preferably, as: capsule, tablet, oral liquid, granule, pill, powder, sublimed preparation, unguentum etc.Granule most preferably.
Pharmaceutical preparation of the present invention, the preparation of its oral administration can contain excipient commonly used, such as binding agent, filler, diluent, tablet agent, lubricant, disintegrating agent, coloring agent, flavoring agent and wetting agent, can carry out coating to tablet in case of necessity.
The filler that is suitable for comprises cellulose, mannitol, lactose and other similar filler.Suitable disintegrating agent comprises starch, polyvinylpyrrolidone and starch derivatives, for example sodium starch glycollate.Suitable lubricant comprises, for example magnesium stearate.The acceptable wetting agent of appropriate drug comprises sodium lauryl sulphate.
Can fill by mixing, the method that tabletting etc. are commonly used prepares solid oral composition.Mix repeatedly active substance is distributed in those compositionss of a large amount of filleies of whole use.
The form of oral liquid for example can be aqueous or oily suspensions, solution, Emulsion, syrup or elixir, perhaps can be a kind of available water before use or other suitable composite dry products of carrier.This liquid preparation can contain conventional additive, such as suspending agent, for example sorbitol, syrup, methylcellulose, gelatin, hydroxyethyl-cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenation edible fat, emulsifying agent, for example lecithin, anhydro sorbitol monooleate or arabic gum; Non-aqueous carrier (they can comprise edible oil), for example almond oil, fractionated coconut oil, such as oily ester, propylene glycol or the ethanol of the ester of glycerol; Antiseptic, for example para hydroxybenzene methyl ester or propyl p-hydroxybenzoate or sorbic acid, and if desired, can contain conventional flavouring agent or coloring agent.
For injection, the liquid unit dosage forms of preparation contains active substance of the present invention and sterile carrier.According to carrier and concentration, this chemical compound can be suspended or dissolving.The preparation of solution is normally by being dissolved in active substance in a kind of carrier filter-sterilized before it is packed into a kind of suitable bottle or ampoule, sealing then.For example a kind of local anesthetic of adjuvant, antiseptic and buffer agent also can be dissolved in this carrier.In order to improve its stability, can be after the bottle of packing into that this compositions is freezing, and under vacuum, water is removed.
Pharmaceutical preparation of the present invention, when being prepared into medicament, optionally add suitable medicine acceptable carrier, described medicine acceptable carrier is selected from: mannitol, sorbitol, sodium pyrosulfite, sodium sulfite, sodium thiosulfate, cysteine hydrochloride, TGA, methionine, vitamin C, the EDTA disodium, EDTA calcium sodium, the alkali-metal carbonate of monovalence, acetate, phosphate or its aqueous solution, hydrochloric acid, acetic acid, sulphuric acid, phosphoric acid, aminoacid, sodium chloride, potassium chloride, sodium lactate, xylitol, maltose, glucose, fructose, dextran, glycine, starch, sucrose, lactose, mannitol, silicon derivative, cellulose and derivant thereof, alginate, gelatin, polyvinylpyrrolidone, glycerol, soil temperature 80, agar, calcium carbonate, calcium bicarbonate, surfactant, Polyethylene Glycol, cyclodextrin, beta-schardinger dextrin-, the phospholipid material, Kaolin, Pulvis Talci, calcium stearate, magnesium stearate etc.
Preparation of the present invention is determined usage and dosage according to patient's situation in use, but obeys every day three times, each 1-20 agent, as: 1-20 bag or grain or sheet.
Chinese medicine preparation of the present invention can prepare by the following method.
Above Six-element, the coarse powder of Caulis Sargentodoxae in will writing out a prescription, Semen Vaccariae, cattail pollen impalpable powder add 80% alcohol reflux secondary, and filtrate merges, and medicinal residues are continued to employ; Filtrate recycling ethanol is not to there being the alcohol flavor, and it is about 1.35 to be evaporated to relative density, and drying is pulverized, and is standby; The coarse powder of the Radix Astragali mixes with medicinal residues after Caulis Sargentodoxae, Semen Vaccariae, the Pollen Typhae alcohol extraction, adds decocting in water and extracts three times, and filtrate merges, and it is about 1.35 to be evaporated to relative density, and drying is pulverized, and is standby; Again Radix Notoginseng, Hirudo merging are ground into impalpable powder, with above-mentioned other extract powder mixings, this mixture is mixed and made into pharmaceutical preparation as the active component of pharmaceutical preparation with the medicine acceptable carrier.
Specifically can be:
The above Six-element Chinese medicine in the prescription, the coarse powder of Caulis Sargentodoxae in will writing out a prescription, Semen Vaccariae, cattail pollen impalpable powder add (7 times of 80% ethanol; 6 times) the reflux, extract, secondary, 2.0 hours for the first time, 1.5 hours for the second time, filtrate merged, and medicinal residues are continued to employ.Filtrate recycling ethanol to do not have the alcohol flavor (vacuum is-0.05～-0.06MPa, temperature is 55～60 ℃), concentrating under reduced pressure (vacuum is-0.07～-0.08MPa, temperature is 60～70 ℃.) to about 1.35 (60 ℃ of heat are surveyed) of relative density, drying is pulverized standby (about 110g).The coarse powder of the Radix Astragali mixes with medicinal residues after Caulis Sargentodoxae, Semen Vaccariae, the Pollen Typhae alcohol extraction, adding decocting in water extracts three times, for the first time add 9 times of water gagings, extracted 1.5 hours, add 8 times of water gagings for the second time, extracted 1.0 hours, add 7 times of water gagings for the third time, extracted 0.5 hour, filtrate merges, concentrating under reduced pressure (vacuum is-0.07～-0.08MPa, temperature is 60～70 ℃.) to about 1.35 (60 ℃ of heat are surveyed) of relative density, drying is pulverized standby (about 580g).Again Radix Notoginseng, Hirudo merging are ground into impalpable powder (about 370g), with above-mentioned other extract powder mixings, add 80% ethanol and make soft material in right amount, 12 mesh sieves are granulated, 60～80 ℃ of dryings.14 mesh sieve granulate, packing, sterilization promptly, is made about 1000g (every g is equivalent to crude drug amount 4.6g).
The Chinese medicine preparation (being called the diffusing silt granule in prostatitis) that the present invention preferably fills a prescription and makes, through No.1 Hospital Attached to Hunan College of Traditional Chinese Medicine 90 routine clinical observations (60 examples are organized in treatment, and other establishes matched group 30 examples), produce effects 23 examples in 60 examples are organized in treatment as a result, effective 29 examples, total effective rate are 86.67%.Compare with matched group, through the Ridit check, P＜0.01, treatment group curative effect is better than matched group.Clinical observation result shows: prostatitis dissipating blood stasis granule can obviously improve patients ' life quality, especially to frequent micturition, the heeltap not to the utmost, doing well,improving such as urgent micturition is very obvious; Show that through abdominal part prostate B ultrasonic treatment cross-reference this medicine can make prostate volume obviously dwindle, its curative effect obviously is better than matched group (P＜0.01); Do not see any toxic and side effects in the observation process.
Pharmacodynamics studies show that before clinical: prostatitis dissipating blood stasis granule high dose has the reduction effect to old dog prostatic hyperplasia, and prostate volume is dwindled, and weight in wet base reduces, and with the blank group significant difference (P＜0.05) is arranged relatively.The visible administration high dose group of tectology inspection dog prostate epithelial cell height reduces, and the lumen of gland diameter diminishes, and biochemical measurement shows that dna content reduces in its prostata tissue, and phosphatase acid serum is active to descend.The diffusing middle and high dosage of silt granule in prostatitis is implanted the mice prostatic hyperplasia that causes to urogenital sinus inhibitory action, wherein high dose group animal body of gland organ coefficient and model group relatively have significant difference, and its tissue DNA content and phosphatase acid serum activity also significantly reduce.And the prostatitis loose each dosage of silt granule to normal mouse and childhood normal rat prostate weight in wet base do not have influence.Acute toxicity and long term toxicity test conventional amount used are not found toxic and side effects.
Pharmacodynamic study:
(1). in the normal mouse test, compare with the blank group, diffusing each dosage of silt granule in prostatitis does not have influence to mice prostate weight in wet base.
(2.) in normal rat test childhood, compare with the blank group, diffusing each dosage of silt granule in prostatitis does not also have influence to the rat prostate weight in wet base.
(3) in the aged spontaneous prostatic hyperplasia dog test, the diffusing silt granule high dose in prostatitis has the reduction effect to old dog prostatic hyperplasia, and prostate volume is dwindled, and weight in wet base reduces, and with the blank group significant difference (p＜0.05) is arranged relatively.The visible administration high dose group of tectology inspection dog prostate epithelial cell height reduces, and the lumen of gland diameter diminishes, and biochemical measurement shows that dna content reduces in its prostata tissue, and phosphatase acid serum is active to descend.
(4.) in the test of urogenital sinus implantation mice prostatic hyperplasia model, the diffusing middle and high dosage of silt granule in prostatitis is implanted the mice prostatic hyperplasia that causes to urogenital sinus inhibitory action, wherein high dose group animal body of gland organ coefficient and model group relatively have significant difference, and its tissue DNA content and phosphatase acid serum activity also significantly reduce.
Toxicologic study
(1) acute toxicity
This experimentation mouse stomach give prostatitis dissipating blood stasis granule acute toxicity test.The result shows: it is 240g crude drug/kg that mouse stomach gives the maximum dosage of prostatitis dissipating blood stasis granule, is equivalent to 208.7 times of clinical medicine dose approximately.
(2) long term toxicity
Rat oral administration long term toxicity test
The SD rat is selected in this experiment for use, and orally give prostatitis dissipating blood stasis granule is studied its repeated multiple times administration long term toxicity test.Dosage is respectively 15,30,60g crude drug/kg.The administration cycle was 26 weeks.Observe following index: overview (as outward appearance sign and behavioral activity, feces character and appetite consumption, body weight change etc.).Hematological indices (red blood cell count(RBC), hemoglobin, total white blood cells and classification thereof, platelet, clotting time).Blood parameters (AST, ALT, ALP, BUN, TP, ALB, GLU, T-BIL, Crea, T-CHO).Routine urine examination,urine for routine is analyzed.System's postmortem and histopathologic examination.The result shows:
1. overview: each treated animal outward appearance sign is normal during the administration, and the initial stage activity of high dose group animals administer has minimizing slightly, and other dosage group is all normal.Body weight all increases, and the high dose group animal increases slow slightly than matched group, but difference does not have the significance meaning.Food-intake, defecation Non Apparent Abnormality.There is not animal dead during the administration.
2. hematological indices: 26 weeks of administration and convalescent period, the every index of hematology (RBC, Hb, WBC, GRAN, MID, LYM, CT), medicine group and matched group relatively, difference does not have the significance meaning.
3. blood parameters: 26 weeks of administration and convalescent period, the every index of blood biochemical (AST, ALT, ALP, BUN, TP, ALB, GLU, T-BIL, Crea, T-CHO), medicine group and matched group relatively, difference does not have the significance meaning.
4. urinalysis: 26 weeks of administration and convalescent period, urine routine (urobilinogen, bilirubin, ketoboidies, occult blood, protein, glucose, PH, nitrite), medicine group and matched group relatively, difference does not have the significance meaning.
5. system's postmortem and histopathologic examination: each treated animal internal organs no abnormality seen of perusal.Internal organs such as the heart, liver, spleen, lung, kidney, adrenal gland, brain, testis, uterus, ovary are weighed, calculate organ coefficient, medicine group and matched group compare as a result, and difference does not have the significance meaning.To histopathology histological examinations such as the heart, liver, spleen, lung, kidney, adrenal gland, thymus, pancreas, thyroid, prostate, testis, epididymis, uterus, ovary, brain, stomach, duodenum, bladders, except that the indivedual internal organs of individual animal have the slight pathological changes, other shows no obvious abnormalities.
According to above results presumption, prostatitis dissipating blood stasis granule rat oral administration, the safe dose in continuous 26 weeks is 30g crude drug/kg.
Beagle dog oral administration long term toxicity test
The Beagle dog is selected in this experiment for use, and repeated multiple times orally give prostatitis dissipating blood stasis granule is studied its long term toxicity.Dosage is respectively 7.5,15,30g crude drug/kg.The administration cycle is June.Observe following index: overview (as behavioral activity, nausea and vomiting, sialorrhea, defecation and appetite consumption, body weight change etc.).Electrocardiographic examination (II lead ECG).Hematological indices (red blood cell count(RBC), hemoglobin, total white blood cells and classification thereof, platelet, clotting time).Blood parameters (AST, ALT, ALP, BUN, TP, ALB, GLU, T-BIL, Crea, T-CHO).Routine urine examination,urine for routine is analyzed.System's postmortem, internal organs are weighed, and calculate organ coefficient and histopathologic examination.Result of the test shows:
1. overview: do not have animal dead during the administration.Movable normal after each dosage treated animal administration, at the administration initial stage, the high dose group individual animal has slight nausea and vomiting reaction or stream birth reaction.Along with the continuation of administration, this reaction fades away.Each treated animal body weight all increases.Food-intake, defecation and ophthalmologic examination Non Apparent Abnormality.
2. electrocardiographic examination: before the administration and during the administration and convalescent period, each index of electrocardiogram (P-R, QRS, Q-T, HR, ST) Non Apparent Abnormality.
3. hematology: before the administration and during the administration and convalescent period, the every index of hematology (RBC, Hb, WBC, GRAN, MID, LYM, CT) all belongs to range of normal value though have unusually.
4. blood parameters: before the administration and during the administration and convalescent period, blood parameters (AST, ALT, ALP, BUN, TP, ALB, GLU, T-BIL, Crea, T-CHO), remove administration latter stage, high dose group AST, ALT have rising trend, but difference does not have outside the significance meaning, and other index all belongs to range of normal value.
5. urinalysis: before the administration, administration phase and convalescent period, urine routine (urobilinogen, bilirubin, ketoboidies, occult blood, protein, glucose, pH value, nitrite, erythrocyte, leukocyte) shows no obvious abnormalities.
6. system's postmortem and histopathologic examination: each treated animal internal organs no abnormality seen of perusal.Internal organs such as the heart, liver, spleen, lung, kidney, adrenal gland, brain, testis, uterus, ovary are weighed, calculate organ coefficient, the result shows medicine group and matched group relatively, and difference does not have the significance meaning.To tissue pathology checkings such as the heart, liver, spleen, lung, kidney, adrenal gland, thyroid, pancreas, prostate, testis, epididymis, uterus, ovary, brain, stomach, duodenum, bladder, optic nervies, except that the indivedual internal organs of individual animal have the slight pathological changes, other shows no obvious abnormalities.
According to above results presumption, Beagle dog oral administration prostatitis dissipating blood stasis granule, continuously June, its safe dose is 15g crude drug/kg.
The clinical research aspect: prostatitis dissipating blood stasis granule be attached chief physician Qiao He Ju of hospital of the college of traditional Chinese medicine through proved recipe, clinical application had two more than ten years.Through No. 1 Hospital Affiliated to Hunan Traditional Chinese Medical College's 90 routine clinical observations (60 examples are organized in treatment, and other establishes matched group 30 examples), produce effects 23 examples in 60 examples are organized in treatment as a result, effective 29 examples, and total effective rate is 86.67%.Compare with matched group, through the Ridit check, P＜0.01, treatment group curative effect is better than matched group.Clinical observation result shows: prostatitis dissipating blood stasis granule can obviously improve patients ' life quality, especially to frequent micturition, the heeltap not to the utmost, doing well,improving such as urgent micturition is very obvious; Show that through abdominal part prostate B ultrasonic treatment cross-reference this medicine can make prostate volume obviously dwindle, its curative effect obviously is better than matched group (P＜0.01); Do not see any toxic and side effects in the observation process.
We have formulated I, II, III phase clinical research plan also according to " new Chinese medicine clinical research guideline " requirement.I phase clinical research intends selecting 34 routine study subjects to test, and mainly observes human body to the particulate tolerance degree of prostatitis dissipating blood stasis, determines the safety range of clinical administration, proposes the suggestion of II clinical trial phase dosage regimen.The II clinical trial phase intend to adopt at random, double blinding dual analog, prostatitis dissipating blood stasis granule and prostate disease granule (1: 1) parallel control, multicenter study method, and planning has 240 routine medicines to be distributed to 5 test centers.Have the clinical effective cases of 200 examples (wherein test group 100 examples, matched group 100 examples) when ensureing off-test at least.Each test center is finished effectively case of 40 examples at least.Entire test lasted for 6 weeks.After finishing the treatment of 6 weeks, carry out final statistical analysis.Clinical plan of III phase is finished 400 example tests (300 examples, matched group 100 examples are organized in treatment).
Following clinical data can further specify beneficial effect of the present invention:
1.1 clinical data
Two groups of patient age, the course of disease, state of an illness total points data see Table 1～3.
Table 1 liang group patient age distribution situation and comparison thereof
| Group | The example number | Age 50～ | 60～ | 70～ | 80～ | 90～ | X ± S (year) |
| Observation group's matched group | 60 30 | 15 7 | 30 15 | 10 6 | 4 2 | 1 0 | 65.8±9.83 65.1±9.24 |
Compare between group (t check): t=0.5638 P＞0.05.
Table 2 liang group patient's course of disease and comparison thereof
| Group | The example number | The course of disease 0.5～ | 1～ | 2～ | 3～ | 4～ | 5～ | X ± S (year) |
| Observation group's matched group | 60 30 | 16 7 | 18 10 | 12 5 | 7 4 | 4 2 | 3 2 | 2.14±1.59 1.96±1.35 |
Compare between group (t check): t=0.3125 P＞0.05
State of an illness total points and comparison thereof before the treatment before the table 3 liang group patient
| Group | The example number | X±S |
| Observation group's matched group | 60 30 | 12.65±4.72 12.35±4.19 |
Compare (t check) t=-0.0327 P＞0.05 between group
Statistical result shows, two groups of patient age, the course of disease, state of an illness total packet differences relatively there are no significant meaning (P＞0.05), illustrate two groups harmonious good, have comparability.
3.2 observation of curative effect result
3.2.1 two groups of clinical efficacies relatively see Table 4.The treatment group relatively has significant difference (u=2.16P＜0.01) with the contrast clinical efficacy, and treatment group curative effect is better than matched group.
Table 4 liang group clinical efficacy relatively
| Group | The example number | Produce effects | Effectively | Invalid | Total effective rate (%) |
| Observation group's matched group | 60 30 | 23 8 | 29 13 | 8 9 | 86.67 70.0 |
Compare between group (Ridit check): u=2.16 p＜0.01
3.2.2 two groups of abdominal part prostate B ultrasonic see Table 5 to the comparison that prostate volume changes.Treatment group and matched group relatively have significant difference (T=8.86 P＜0.01).
3.2.2 two groups of abdominal part prostate B ultrasonic relatively see Table 5 to what prostate volume changed.Treatment group and matched group relatively have significant difference (T=8.86 P＜0.01).
Table 5 liang group B ultrasonic prostate volume (cm
2) change relatively
| Before the treatment (X ± S) | The treatment back (X ± S) | T | P | |
| Treatment group matched group | 45.85±3.13 45.43±2.94 | 27.14±4.96 36.56±4.11 | 26.70 12.55 | P＜0.01 P＜0.01 |
T＝0.61，p＞0.05 T＝8.86，P＜0.01
The result shows: relatively, P＞0.05 illustrates that treatment has comparability for preceding two groups before two groups of treatments; Compare (P＜0.01) before and after the treatment of treatment group, illustrate that treatment group treatment front volume difference has statistical significance.(P＜0.01) is compared in two groups of treatment backs, illustrates that two groups of data treatment back differences have statistical significance.Prostate volume changes before and after two groups of treatments, through T check (P＜0.01), illustrates that the curative effect of treatment group is better than matched group.
4. brief summary
Show through clinical observation result:
1. the preparation of the present invention of observation group can obviously improve patients ' life quality, especially to frequent micturition, the heeltap not to the utmost, doing well,improving such as urgent micturition is very obvious.
2. show that through abdominal part prostate B ultrasonic treatment cross-reference this medicine can make prostate volume obviously dwindle, its curative effect obviously is better than matched group (P＜0.01).
3. this medicine safety is without any side effects.
Chinese medicine preparation of the present invention, its innovative point has three: one, and this product can benefiting QI for activating blood circulation, again can hard masses softening and resolving, the basic pathogenesis of the blood stasis due to qi deficiency that links closely be can yet be regarded as and treated the good medicine of prostatic hyperplasia.The 2nd, fully use the modern scientific research achievement.Selected medicine modern study confirms that the effect that reduces prostatic hyperplasia is preferably arranged, and prostate volume is dwindled, and weight in wet base reduces and do not see tangible toxicity.The 3rd, effective Chinese patent medicine of treatment prostatic hyperplasia is few on the present Chinese medicine market, and the selected medicine medicine of the present invention source is wide, easy to utilize.
The specific embodiment:
Further specify the present invention by the following examples.
Embodiment 1
Prescription:
Radix Astragali 2000.0g Caulis Sargentodoxae 1000.0g Semen Vaccariae 666.6g
Pollen Typhae 533.4g Radix Notoginseng 200.0g Hirudo 200.0g
Technology:
Above Six-element, Caulis Sargentodoxae, the coarse powder of Semen Vaccariae, cattail pollen impalpable powder add (7 times of 80% ethanol in will writing out a prescription; 6 times) the reflux, extract, secondary, 2.0 hours for the first time, 1.5 hours for the second time, filtrate merged, and medicinal residues are continued to employ.Filtrate recycling ethanol to do not have the alcohol flavor (vacuum is-0.05～-0.06MPa, temperature is 55～60 ℃), concentrating under reduced pressure (vacuum is-0.07～-0.08MPa, temperature is 60～70 ℃.) to about 1.35 (60 ℃ of heat are surveyed) of relative density, drying is pulverized standby (about 110g).The coarse powder of the Radix Astragali mixes with medicinal residues after Caulis Sargentodoxae, Semen Vaccariae, the Pollen Typhae alcohol extraction, adding decocting in water extracts three times, for the first time add 9 times of water gagings, extracted 1.5 hours, add 8 times of water gagings for the second time, extracted 1.0 hours, add 7 times of water gagings for the third time, extracted 0.5 hour, filtrate merges, concentrating under reduced pressure (vacuum is-0.07～-0.08MPa, temperature is 60～70 ℃.) to about 1.35 (60 ℃ of heat are surveyed) of relative density, drying is pulverized standby (about 580g).Again Radix Notoginseng, Hirudo merging are ground into impalpable powder (about 370g), with above-mentioned other extract powder mixings, add 80% ethanol and make soft material in right amount, 12 mesh sieves are granulated, 60～80 ℃ of dryings.14 mesh sieve granulate, packing, sterilization promptly, is made about 1000g (every g is equivalent to crude drug amount 4.6g).
Embodiment 2
Prescription:
Radix Astragali 1000g Caulis Sargentodoxae 500g Semen Vaccariae 333g
Pollen Typhae 266g Radix Notoginseng 100g Hirudo 100g
Technology:
Above Six-element, Caulis Sargentodoxae, the coarse powder of Semen Vaccariae, cattail pollen impalpable powder add (7 times of 80% ethanol in will writing out a prescription; 6 times) the reflux, extract, secondary, 2.0 hours for the first time, 1.5 hours for the second time, filtrate merged, and medicinal residues are continued to employ.Filtrate recycling ethanol to do not have the alcohol flavor (vacuum is-0.05～-0.06MPa, temperature is 55～60 ℃), concentrating under reduced pressure (vacuum is-0.07～-0.08MPa, temperature is 60～70 ℃.) to about 1.35 (60 ℃ of heat are surveyed) of relative density, drying is pulverized standby (about 110g).The coarse powder of the Radix Astragali mixes with medicinal residues after Caulis Sargentodoxae, Semen Vaccariae, the Pollen Typhae alcohol extraction, adding decocting in water extracts three times, for the first time add 9 times of water gagings, extracted 1.5 hours, add 8 times of water gagings for the second time, extracted 1.0 hours, add 7 times of water gagings for the third time, extracted 0.5 hour, filtrate merges, concentrating under reduced pressure (vacuum is-0.07～-0.08MPa, temperature is 60～70 ℃.) to about 1.35 (60 ℃ of heat are surveyed) of relative density, drying is pulverized standby (about 580g).Again Radix Notoginseng, Hirudo merging are ground into impalpable powder (about 370g), with above-mentioned other extract powder mixings, add 80% ethanol and make soft material in right amount, 12 mesh sieves are granulated, 60～80 ℃ of dryings.14 mesh sieve granulate, packing, sterilization promptly, is made about 1000g.
Embodiment 3
Prescription:
Radix Astragali 4000g Caulis Sargentodoxae 2000g Semen Vaccariae 1332g
Pollen Typhae 1066g Radix Notoginseng 400g Hirudo 400g
Technology:
Above Six-element, Caulis Sargentodoxae, the coarse powder of Semen Vaccariae, cattail pollen impalpable powder add (7 times of 80% ethanol in will writing out a prescription; 6 times) the reflux, extract, secondary, 2.0 hours for the first time, 1.5 hours for the second time, filtrate merged, and medicinal residues are continued to employ.Filtrate recycling ethanol to do not have the alcohol flavor (vacuum is-0.05～-0.06MPa, temperature is 55～60 ℃), concentrating under reduced pressure (vacuum is-0.07～-0.08MPa, temperature is 60～70 ℃.) to about 1.35 (60 ℃ of heat are surveyed) of relative density, drying is pulverized standby (about 110g).The coarse powder of the Radix Astragali mixes with medicinal residues after Caulis Sargentodoxae, Semen Vaccariae, the Pollen Typhae alcohol extraction, adding decocting in water extracts three times, for the first time add 9 times of water gagings, extracted 1.5 hours, add 8 times of water gagings for the second time, extracted 1.0 hours, add 7 times of water gagings for the third time, extracted 0.5 hour, filtrate merges, concentrating under reduced pressure (vacuum is-0.07～-0.08MPa, temperature is 60～70 ℃.) to about 1.35 (60 ℃ of heat are surveyed) of relative density, drying is pulverized standby (about 580g).Again Radix Notoginseng, Hirudo merging are ground into impalpable powder (about 370g), with above-mentioned other extract powder mixings, add 80% ethanol and make soft material in right amount, 12 mesh sieves are granulated, 60～80 ℃ of dryings.14 mesh sieve granulate, packing, sterilization promptly, is made about 1000g
Embodiment 4
Prescription:
Radix Astragali 1500g Caulis Sargentodoxae 750g Semen Vaccariae 499g
Pollen Typhae 399g Radix Notoginseng 150g Hirudo 150g
Technology:
Above Six-element, Caulis Sargentodoxae, the coarse powder of Semen Vaccariae, cattail pollen impalpable powder add (7 times of 80% ethanol in will writing out a prescription; 6 times) the reflux, extract, secondary, 2.0 hours for the first time, 1.5 hours for the second time, filtrate merged, and medicinal residues are continued to employ.Filtrate recycling ethanol to do not have the alcohol flavor (vacuum is-0.05～-0.06MPa, temperature is 55～60 ℃), concentrating under reduced pressure (vacuum is-0.07～-0.08MPa, temperature is 60～70 ℃.) to about 1.35 (60 ℃ of heat are surveyed) of relative density, drying is pulverized standby (about 110g).The coarse powder of the Radix Astragali mixes with medicinal residues after Caulis Sargentodoxae, Semen Vaccariae, the Pollen Typhae alcohol extraction, adding decocting in water extracts three times, for the first time add 9 times of water gagings, extracted 1.5 hours, add 8 times of water gagings for the second time, extracted 1.0 hours, add 7 times of water gagings for the third time, extracted 0.5 hour, filtrate merges, concentrating under reduced pressure (vacuum is-0.07～-0.08MPa, temperature is 60～70 ℃.) to about 1.35 (60 ℃ of heat are surveyed) of relative density, drying is pulverized standby (about 580g).Again Radix Notoginseng, Hirudo merging are ground into impalpable powder (about 370g), with above-mentioned other extract powder mixings, add 80% ethanol and make soft material in right amount, 12 mesh sieves are granulated, 60～80 ℃ of dryings.14 mesh sieve granulate, packing, sterilization promptly, is made about 1000g
Embodiment 5
Prescription:
Radix Astragali 2666g Caulis Sargentodoxae 1333g Semen Vaccariae 888g
Pollen Typhae 710g Radix Notoginseng 266g Hirudo 266g
Technology:
Above Six-element, Caulis Sargentodoxae, the coarse powder of Semen Vaccariae, cattail pollen impalpable powder add (7 times of 80% ethanol in will writing out a prescription; 6 times) the reflux, extract, secondary, 2.0 hours for the first time, 1.5 hours for the second time, filtrate merged, and medicinal residues are continued to employ.Filtrate recycling ethanol to do not have the alcohol flavor (vacuum is-0.05～-0.06MPa, temperature is 55～60 ℃), concentrating under reduced pressure (vacuum is-0.07～-0.08MPa, temperature is 60～70 ℃.) to about 1.35 (60 ℃ of heat are surveyed) of relative density, drying is pulverized standby (about 110g).The coarse powder of the Radix Astragali mixes with medicinal residues after Caulis Sargentodoxae, Semen Vaccariae, the Pollen Typhae alcohol extraction, adding decocting in water extracts three times, for the first time add 9 times of water gagings, extracted 1.5 hours, add 8 times of water gagings for the second time, extracted 1.0 hours, add 7 times of water gagings for the third time, extracted 0.5 hour, filtrate merges, concentrating under reduced pressure (vacuum is-0.07～-0.08MPa, temperature is 60～70 ℃.) to about 1.35 (60 ℃ of heat are surveyed) of relative density, drying is pulverized standby (about 580g).Again Radix Notoginseng, Hirudo merging are ground into impalpable powder (about 370g), with above-mentioned other extract powder mixings, add 80% ethanol and make soft material in right amount, 12 mesh sieves are granulated, 60～80 ℃ of dryings.14 mesh sieve granulate, packing, sterilization promptly, is made about 1000g.
Claims (10)
1, a kind of Chinese medicine preparation for the treatment of prostatic hyperplasia, make by following Chinese medicinal raw materials:
Radix Astragali 1000-4000 part Caulis Sargentodoxae 500-2000 part Semen Vaccariae 333-1332 part
Pollen Typhae 266-1066 part Radix Notoginseng 100-400 part Hirudo 100-400 part.
2, the Chinese medicine preparation of claim 1, make by following Chinese medicinal raw materials:
Radix Astragali 1500-2666 part Caulis Sargentodoxae 750-1333 part Semen Vaccariae 499-888 part
Pollen Typhae 399-710 part Radix Notoginseng 150-266 part Hirudo 150-266 part.
3, the Chinese medicine preparation of claim 1, make by following Chinese medicinal raw materials:
666.6 parts of 1000.0 parts of Semen Vaccariae of 2000.0 portions of Caulis Sargentodoxae of the Radix Astragali
200.0 parts of 200.0 portions of Hirudos of 533.4 portions of Radix Notoginseng of Pollen Typhae.
4, the Chinese medicine preparation of claim 1 is selected from: tablet, capsule, oral liquid, granule, pill, powder, unguentum, sublimed preparation, suspensoid, powder, solution, suppository, drop pill, patch.
5, the Chinese medicine preparation of claim 1 is a granule.
6, the preparation method of the Chinese medicine preparation of claim 1 is characterized in that, through following steps: above Six-element, with the coarse powder of Caulis Sargentodoxae, Semen Vaccariae, cattail pollen impalpable powder, add 80% alcohol reflux secondary, filtrate merges, and medicinal residues are continued to employ; Filtrate recycling ethanol is evaporated to relative density 1.35 to there not being the alcohol flavor, and drying is pulverized, and is standby; The coarse powder of the Radix Astragali mixes with medicinal residues after Caulis Sargentodoxae, Semen Vaccariae, the Pollen Typhae alcohol extraction, adds decocting in water and extracts three times, and filtrate merges, and is evaporated to relative density 1.35, and drying is pulverized, and is standby; Again Radix Notoginseng, Hirudo merging are ground into impalpable powder, with above-mentioned other extract powder mixings, this mixture is mixed and made into Chinese medicine preparation as the active component of Chinese medicine preparation with the medicine acceptable carrier.
7, the preparation method of claim 6 is characterized in that, the described 80% alcohol reflux secondary that adds is 2.0 hours for the first time, 1.5 hours for the second time.
8, the preparation method of claim 6 is characterized in that, the described decocting in water that adds extracts three times, is to add 9 times of water gagings for the first time, extracts 1.5 hours, adds 8 times of water gagings for the second time, extracts 1.0 hours, adds 7 times of water gagings for the third time, extracts 0.5 hour.
9, the preparation method of claim 6 is characterized in that, the active component of the Chinese medicine preparation that makes adds 80% ethanol system soft material, and 12 mesh sieves are granulated, 60～80 ℃ of dryings, and 14 mesh sieve granulate, packing, sterilization makes granule.
10, the application of the Chinese medicine preparation of claim 1 in the medicine of preparation treatment prostatic hyperplasia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100539198A CN100342888C (en) | 2005-03-14 | 2005-03-14 | Chinese medicine preparation for treating prostatic hyperplasia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100539198A CN100342888C (en) | 2005-03-14 | 2005-03-14 | Chinese medicine preparation for treating prostatic hyperplasia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1682954A CN1682954A (en) | 2005-10-19 |
| CN100342888C true CN100342888C (en) | 2007-10-17 |
Family
ID=35262573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100539198A Expired - Fee Related CN100342888C (en) | 2005-03-14 | 2005-03-14 | Chinese medicine preparation for treating prostatic hyperplasia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100342888C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101601741B (en) * | 2008-03-07 | 2012-05-30 | 刘墨林 | Diuretic medicine |
| CN101461841B (en) * | 2009-01-09 | 2011-02-16 | 黄卫忠 | Chinese patent medicine for treating prostatoplasia |
| CN102727716B (en) * | 2012-07-13 | 2013-09-18 | 山东省中医药研究院 | Traditional Chinese medicine preparation for treating dampness-heat blood stasis type chronic prostatitis |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1294013A (en) * | 1999-10-26 | 2001-05-09 | 马俊杰 | Medicine for treating prostatic hyperplasia |
-
2005
- 2005-03-14 CN CNB2005100539198A patent/CN100342888C/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1294013A (en) * | 1999-10-26 | 2001-05-09 | 马俊杰 | Medicine for treating prostatic hyperplasia |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1682954A (en) | 2005-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100342889C (en) | Chinese medicine for treating gout | |
| CN101732683A (en) | Chinese medicinal preparation for treating facial chloasma and preparation method thereof | |
| CN1857618A (en) | Chinese medicine preparation for reducing sugar | |
| CN1857690A (en) | Gynecopathy treating preparation and its preparing process | |
| CN1857668A (en) | Chloasma treating Chinese medicine preparation | |
| CN106362020B (en) | A kind of pine pollen composition and preparation method thereof with improvement defecating feces excretion | |
| CN1977959A (en) | Chinese medicine compound preparation for comprehensively regulating body function and its preparing method | |
| CN102671178B (en) | Preparation method of Chinese medicinal composition for treating nephrotic syndrome and uremia and application thereof | |
| CN100462101C (en) | Medicament for treating aplastic anemia | |
| CN100342888C (en) | Chinese medicine preparation for treating prostatic hyperplasia | |
| CN1899590A (en) | Gynecological Chinese patented medicine for relieving depressed liver and clearing heat, strengthening spleen and nourishing blood and its preparing method | |
| CN1060657C (en) | Nourishing medicine for preventing and curing toxic and side effect after tumor radiotherapy and chemotherapy and preparation method | |
| CN1679697A (en) | Chinese medicine preparation for treating cardio vascular disease and containing notoginseng, pericarpium trichosanthis and leech, for treating cardio-cerebral blood vessel diseases and its preparing | |
| CN1814163A (en) | Chinese medicine for treating cardiovascular and cerebrovascular trrombus and preparing method | |
| CN100563706C (en) | A kind of pharmaceutical composition that is used for infantile diarrhea | |
| CN1279964C (en) | Chinese medicine for regulating menstruation and nourishing blood | |
| CN1308024C (en) | Medicine for treating diabetes and its preparing method | |
| CN107753800A (en) | A kind of Chinese medicine composition for treating chronic pelvic inflammatory disease and preparation method thereof | |
| CN1309412C (en) | Medicine composition for treating AIDS and preparing method thereof | |
| CN100333777C (en) | Medicine for improving enterogastric function after radiation chemiotherapy | |
| CN102949606A (en) | Chinese medicinal composition for treating female climacteric syndrome | |
| CN100363051C (en) | Mastoproliferation treating Chinese medicine and its prepn | |
| CN101036742A (en) | Medicine for treating prostatic disease | |
| CN1296091C (en) | Chinese traditional medicine composition for treating psoriasis | |
| CN1733190A (en) | Chinese traditional medicine preparation for curing mastopathy in installments |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20071017 |